Researchers at Yale School of Medicine have used a new drug compound to successfully reverse brain deficits caused by Alzheimer’s in animal models. The compound, TC-2153, inhibits the negative effects of a protein called STtriatal-Enriched tyrosine Phosphatase (STEP)–a process that scientists found is key to restoring functions in learning and memory.
The researchers examined thousands of molecules in order to identify which would inhibit the STEP protein. The inhibiting molecules were then tested to see how effective they were, and the most promising compound was tested in a mouse model with Alzheimer’s. Researchers found the TC-2153 compound to reverse deficits in the animals’ cognitive functions when testing their memory on previously seen objects.
Mice are not people. Still, this seems hopeful. As does this:
In the current study experiments, mice with the Alzheimer’s gene mutations expressing human APOE3 or APOE4 were able to complete cognitive tests just as well as their non-Alzheimer’s counterparts 10 days after starting treatment with bexarotene.
The mice underwent a spatial test that used cues to detect a hidden platform in a water maze, and a long-term memory test of the mouse’s skills in distinguishing between two familiar objects following introduction to a third, new object.
Bexarotene treatment has no impact on the weight or general behavior of the mice. The drug was was successful in both male and female mice.
I want to see the results of testing in humans. Faster, please.
I’ve thought for a long time that we would start to see major human diseases like cancer, CVD, and Alzheimer’s fall to the advances of medical science in the technological era. I think the next ten years will see most of them conquered, and at least the beginnings of effective life extension treatments.